NEW YORK (GenomeWeb News) — Roche said today that it has acquired Iquum, a privately held company developing point-of-care molecular diagnostics.

Under the terms of the agreement, Roche will pay Iquum shareholders $275 million upfront and up to $175 million in contingent product-related milestones. Once the transaction is complete, pending customary closing conditions, Marlborough, Mass.-based IQuum will be integrated into Roche Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.